![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: NFATC2 |
Gene summary for NFATC2 |
![]() |
Gene information | Species | Human | Gene symbol | NFATC2 | Gene ID | 4773 |
Gene name | nuclear factor of activated T cells 2 | |
Gene Alias | NFAT1 | |
Cytomap | 20q13.2 | |
Gene Type | protein-coding | GO ID | GO:0000122 | UniProtAcc | Q13469 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
4773 | NFATC2 | PTCwithoutHT_2 | Human | Thyroid | PTC | 2.43e-03 | -1.98e-01 | 0.0419 |
4773 | NFATC2 | male-WTA | Human | Thyroid | PTC | 7.65e-06 | -1.13e-01 | 0.1037 |
4773 | NFATC2 | PTC05 | Human | Thyroid | PTC | 1.29e-04 | -4.61e-02 | 0.2065 |
4773 | NFATC2 | PTC07 | Human | Thyroid | PTC | 2.66e-03 | -1.18e-01 | 0.2044 |
4773 | NFATC2 | ATC13 | Human | Thyroid | ATC | 2.12e-27 | 8.42e-01 | 0.34 |
4773 | NFATC2 | ATC5 | Human | Thyroid | ATC | 2.17e-34 | 9.50e-01 | 0.34 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Thyroid | ![]() | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis | ||
PTC: Papillary thyroid cancer |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0009410111 | Thyroid | PTC | response to xenobiotic stimulus | 171/5968 | 462/18723 | 1.00e-02 | 4.07e-02 | 171 |
GO:004269216 | Thyroid | ATC | muscle cell differentiation | 165/6293 | 384/18723 | 7.17e-05 | 5.46e-04 | 165 |
GO:005114617 | Thyroid | ATC | striated muscle cell differentiation | 119/6293 | 283/18723 | 1.74e-03 | 8.70e-03 | 119 |
GO:005500112 | Thyroid | ATC | muscle cell development | 81/6293 | 184/18723 | 2.02e-03 | 9.60e-03 | 81 |
GO:000941027 | Thyroid | ATC | response to xenobiotic stimulus | 184/6293 | 462/18723 | 2.70e-03 | 1.23e-02 | 184 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 2 3 4 5 6 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
NFATC2 | SNV | Missense_Mutation | c.1279N>A | p.Glu427Lys | p.E427K | Q13469 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A2-A0YK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | |
NFATC2 | SNV | Missense_Mutation | c.1505N>A | p.Pro502His | p.P502H | Q13469 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A8-A07L-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | CR | ||
NFATC2 | SNV | Missense_Mutation | rs748148486 | c.1433N>A | p.Arg478Gln | p.R478Q | Q13469 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-A8-A08G-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR |
NFATC2 | SNV | Missense_Mutation | rs774385491 | c.827N>T | p.Ser276Leu | p.S276L | Q13469 | protein_coding | deleterious(0.01) | probably_damaging(0.986) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
NFATC2 | SNV | Missense_Mutation | novel | c.349N>G | p.Pro117Ala | p.P117A | Q13469 | protein_coding | tolerated(0.11) | benign(0.266) | TCGA-BH-A0B6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
NFATC2 | SNV | Missense_Mutation | c.1992N>C | p.Lys664Asn | p.K664N | Q13469 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-C8-A26W-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | CR | |
NFATC2 | insertion | Nonsense_Mutation | novel | c.1033_1034insAAAAAATAAAAATAAAAATTGAGTACCTAAATAGATAAAGGTAGAGC | p.Ile345LysfsTer13 | p.I345Kfs*13 | Q13469 | protein_coding | TCGA-B6-A0IA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
NFATC2 | insertion | In_Frame_Ins | novel | c.918_919insTTGTTCACCCCCATACCAGATGAAAATGGACAG | p.Leu307_Asn308insPheThrProIleProAspGluAsnGlyGlnLeu | p.L307_N308insFTPIPDENGQL | Q13469 | protein_coding | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | ||
NFATC2 | deletion | Frame_Shift_Del | novel | c.898delN | p.Ser300LeufsTer3 | p.S300Lfs*3 | Q13469 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
NFATC2 | SNV | Missense_Mutation | rs777046802 | c.2048N>T | p.Thr683Met | p.T683M | Q13469 | protein_coding | deleterious(0) | probably_damaging(0.971) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
4773 | NFATC2 | TRANSCRIPTION FACTOR BINDING, TRANSCRIPTION FACTOR COMPLEX, DRUGGABLE GENOME | asparaginase | ASPARAGINASE | 25987655 |
Page: 1 |